Therapeutic agents for reducing parathyroid hormone levels
    1.
    发明授权
    Therapeutic agents for reducing parathyroid hormone levels 有权
    降低甲状旁腺激素水平的治疗剂

    公开(公告)号:US08377880B2

    公开(公告)日:2013-02-19

    申请号:US13365213

    申请日:2012-02-02

    摘要: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2—X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

    摘要翻译: 描述了具有降低甲状旁腺激素水平的活性的化合物。 在一个实施方案中,化合物由亚单位X1-X2-X3-X4-X5-X6-X7的连续序列组成,其中X1亚基包含含巯基的部分,并且X2-X7亚基上的电荷分布 提供所需的活动。 还描述了使用该化合物治疗甲状旁腺功能亢进,骨疾病和/或高钙血症的方法,特别是提供降低血浆PTH和血清钙的方法。 这些化合物可用于治疗患有例如:原发性,继发性或甲状腺功能亢进的受试者; 恶性高钙血症; 转移性骨病; 或骨质疏松。

    Therapeutic agents for reducing parathyroid hormone levels
    2.
    发明授权
    Therapeutic agents for reducing parathyroid hormone levels 有权
    降低甲状旁腺激素水平的治疗剂

    公开(公告)号:US08999932B2

    公开(公告)日:2015-04-07

    申请号:US12846724

    申请日:2010-07-29

    摘要: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

    摘要翻译: 描述了具有降低甲状旁腺激素水平的活性的化合物。 在一个实施方案中,化合物由亚单位X1-X2-X3-X4-X5-X6-X7的连续序列组成,其中X1亚基包含含巯基的部分,并且X2-X7亚基上的电荷分布 提供所需的活动。 还描述了使用该化合物治疗甲状旁腺功能亢进,骨疾病和/或高钙血症的方法,特别是提供降低血浆PTH和血清钙的方法。 这些化合物可用于治疗患有例如:原发性,继发性或甲状腺功能亢进的受试者; 恶性高钙血症; 转移性骨病; 或骨质疏松。

    THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS
    3.
    发明申请
    THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS 有权
    用于减少帕拉霉素激素水平的治疗药物

    公开(公告)号:US20110028394A1

    公开(公告)日:2011-02-03

    申请号:US12846724

    申请日:2010-07-29

    摘要: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

    摘要翻译: 描述了具有降低甲状旁腺激素水平的活性的化合物。 在一个实施方案中,化合物由亚单位X1-X2-X3-X4-X5-X6-X7的连续序列组成,其中X1亚基包含含巯基的部分,并且X2-X7亚基上的电荷分布 提供所需的活动。 还描述了使用该化合物治疗甲状旁腺功能亢进,骨疾病和/或高钙血症的方法,特别是提供降低血浆PTH和血清钙的方法。 这些化合物可用于治疗患有例如:原发性,继发性或甲状腺功能亢进的受试者; 恶性高钙血症; 转移性骨病; 或骨质疏松。